Catalyst Wire Dossier Catalyst Wire Dossier

DUPIXENT

DUPILUMAB · sanofi-aventis U.S. LLC
Drug timelines are a Plus or Pro feature.

87 regulatory and trial events tracked for DUPIXENT, covering 2016-08-22 to 2026-08-18. Get the full timeline:

Most recent: EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

See pricing